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Background: Live attenuated inﬂuenza vaccine (LAIV) was licensed in 2003 in the United States for use in
individuals aged 5–49 years.
Methods: A prospective observational postmarketing study was conducted to evaluate the safety of LAIV.
Rates of medically attended events (MAEs) and serious adverse events (SAEs) in eligible children aged
5–17 years receiving LAIV as part of routine care from October 2003 to March 2008 were compared with
rates in nonrandomized self, matched unvaccinated, andmatched trivalent inactivated inﬂuenza vaccine
(TIV)-vaccinated controls. AllMAEsandSAEs through42dayspostvaccinationandall hospitalizations and
deaths through 6 months postvaccination were analyzed. Statistical signiﬁcance was assigned without
multiplicity adjustment.
Results: 43,702 LAIV recipients were matched with similar numbers of TIV-vaccinated and unvaccinated
children. Of approximately 9500 MAE incidence rate comparisons, 204 were statistically signiﬁcantly
higher and 168 were statistically signiﬁcantly lower in LAIV recipients versus controls. No pattern of
MAE rate differences suggested a safety signal with LAIV. Asthma/wheezing MAEs were not statistically
increased in LAIV recipients. No anaphylaxis events occurredwithin 3 days postvaccination. Rates of SAEs
were similar between LAIV and control groups. Two SAEswere considered possibly related to LAIV: Bell’s
palsy and nonspeciﬁc paroxysmal spell.
Conclusions: Results of this postlicensure evaluation of LAIV safety in US children aged 5–17 years are
consistent with preapproval clinical studies and Vaccine Adverse Event Reporting System reports, both
of which demonstrated no signiﬁcant increase in asthma/wheezing events or other adverse outcomes
among eligible children who received LAIV.. Introduction
Inﬂuenza is a major cause of morbidity in people of all ages.
he primary strategy for the prevention of inﬂuenza is vaccination.
nactivated inﬂuenza vaccines have been recommended since the
960s for the elderly and thosewithunderlyingmedical conditions.
Abbreviations: ED, emergency department; FU, follow-up; HR, hazard ratio; KP,
aiser Permanente; LAIV, intranasal live attenuated inﬂuenza vaccine; MAE, med-
cally attended event; NE, not estimated; PSDI, prespeciﬁed diagnoses of interest;
AD, reactive airway disease; RR, relative risk; SAE, serious adverse event; SOB,
hortness of breath; TIV, injectable trivalent inactivated inﬂuenza vaccine.
∗ Corresponding author. Tel.: +1 301 398 4734; fax: +1 301 398 9734.
E-mail addresses: roger.baxter@kp.org (R. Baxter), tobacks@medimmune.com
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oan.bartlett@kp.org (J. Bartlett), laurie.a.aukes@kp.org (L. Aukes), ned.lewis@kp.org
N. Lewis), wux@medimmune.com (X. Wu), ambrosec@medimmune.com
C.S. Ambrose).
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In 2004, the Centers for Disease Control and Prevention Advisory
Committee on Immunization Practices recommended vaccination
against inﬂuenza for all children aged 6–23 months [1]; in 2008,
this recommendation was expanded to include all children and
adolescents through 18 years of age [2].
In the United States, intranasal live attenuated inﬂuenza vac-
cine (LAIV) and injectable trivalent inactivated inﬂuenza vaccine
(TIV) are approved for use in eligible children and adolescents.
Some TIV formulations are approved for use in eligible children
6 months and older. The Ann Arbor strain LAIV (MedImmune, LLC,
Gaithersburg, MD) was licensed in 2003 for use in eligible individ-
uals aged 5–49 years. Initially, LAIV was not approved for use in
children younger than 5 years because an increased rate of asthma
andwheezing events was noted in young children in one study [3].
A subsequent study that was prospectively designed to evaluate
wheezing showed an increased rate of medically attended wheez-
ing in LAIV-vaccinated children aged <24months, with no increase
in LAIV-vaccinated children ≥24 months of age [4,5]. Based on this
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tudy, in 2007 the US Food and Drug Administration expanded its
pproval of LAIV to include children aged 24–59 months [6]. From
he initial approval of LAIV through the 2011–2012 season, more
han 50 million doses have been distributed for use in the United
tates, with use predominantly occurring among children, military
ersonnel, and healthcare workers.
During prelicensure clinical trials, the safety of LAIV was  evalu-
ted in 26,031 children aged 2–18 years, including data from 14
lacebo-controlled studies (N = 10,693), 6 TIV-controlled studies
N = 4245) and 1 community-based open-label study (N = 11,096)
7,8]. Previous comparative studies of LAIV and TIV have generally
emonstrated comparable safety of the 2 vaccines among individu-
ls ≥2 years of age, with most adverse reactions from either vaccine
eing mild, transient, and of minimal clinical signiﬁcance [7]. At
he time of the initial approval of LAIV in the United States, Med-
mmune committed to the US Food and Drug Administration to
onduct a postmarketing evaluation of the safety of LAIV in 60,000
AIV recipients 5–49 years of age, with 20,000 individuals each
ged 5–8 years, 9–17 years, and 18–49 years. The intent of this
ostmarketing study was to conduct a broad assessment of safety,
valuating all events and speciﬁc prespeciﬁed events. The current
nalysis describes the results among children 5–8 years and 9–17
ears of age; results for adults 18–49 years of age will be reported
eparately.
. Methods
.1. Study design
Kaiser  Permanente (KP) health plan is a large integrated health
aintenance organization with medical centers in multiple areas
f the United States. The KP database was previously used to eval-
ate the safety of LAIV in a randomized, placebo-controlled study
3]. The current study was a prospective observational study and
ollected data from the Northern California, Hawaii, and Colorado
P sites, where inclusive membership totals approximately 4 mil-
ion individuals. All medical care for members is provided through
he health plan, and clinic visits and treatments are documented
n comprehensive databases. Inﬂuenza vaccines are provided to
ll members at no cost, and extensive programs are in place to
nsure rapid and convenient distribution of vaccines to members
ach year.
Commercially available LAIV was supplied each year by Med-
mmune, and commercially available TIV was purchased by KP as
art of routine practice. Each annual formulation of the vaccines
ontained the strains recommended for inclusion by the US Pub-
ic Health Service. Subjects were screened for underlying medical
onditions and provided the appropriate vaccine based on the eligi-
ility criteria in each vaccine’s package insert, physician discretion,
nd patient choice. The protocol was reviewed and approved by the
P Institutional Review Board.
The study’s objective was to assess the safety of LAIV, by com-
aring the rates of medically attended events (MAEs) in LAIV
ecipients, including all MAEs by diagnosis and speciﬁcally serious
dverse events (SAEs), anaphylaxis, urticaria, asthma, wheezing,
respeciﬁed diagnoses of interest, and rare events potentially
elated to wild-type inﬂuenza, to the rates in 3 nonrandomized
ontrol groups.
.2.  Study populationsThrough  KP immunization registries, approximately 40,000
ndividuals 5–17 years of age who were immunized with LAIV as
art of routine clinical practice were identiﬁed from the 2003–2004
hrough the 2007–2008 inﬂuenza seasons. The population included (2012) 2989– 2998
approximately  20,000 individuals in each of 2 age groups; 5–8 years
and 9–17 years. Subjects from 5 to 8 years of age may  have received
1 or 2 doses of LAIV in accordance with inﬂuenza vaccination rec-
ommendations whereas subjects ≥9 years of age were expected
to receive only 1 dose. Study subjects with high-risk underlying
medical conditions such as cancer, organ transplantation, diabetes,
endocrine and metabolic disorders, blood disorders, liver disor-
ders, kidney disorders and cardiopulmonary disorders (for whom
LAIV was not recommended) were identiﬁed via automated extrac-
tion of healthcare databases and were excluded from analysis in all
cohorts.
Three nonrandomized control groups were identiﬁed for
comparison: a within-cohort (i.e., self-control) control, matched
concurrent unvaccinated controls, and matched concurrent TIV
recipient controls. For the within-cohort analysis, LAIV recipients
served as their own controls based on the observation time after
vaccination. Risk intervals of 3 and 21 days postvaccination were
compared with control intervals from 4 to 42 days postvaccination
(for the 3-day risk interval) and 22 to 42 days postvaccination (for
a 0- to 21-day risk interval). Unvaccinated controls were selected
from the pool of individuals who  were members of KP during the
same month that the reference LAIV recipient was vaccinated and
included those who did not receive TIV or LAIV. For the unvacci-
nated population, the effective vaccination date was the date on
which the matched LAIV recipient was  vaccinated. TIV-vaccinated
controls were selected from the pool of individuals who received
TIV but not LAIV during the same month that the reference LAIV
recipient was vaccinated. Other matching factors included region
(Northern California, Colorado, Hawaii), age (within 1 year), sex,
prior year healthcare use (number of hospital, emergency depart-
ment [ED], and clinic visits), and speciﬁc medical center (only for
subjects from Northern California, where there were 48 clinics).
Dose number (ﬁrst or second dose in those 5–8 years of age) was
also matched between LAIV recipients and TIV controls for subjects
from Northern California and Hawaii; matching by dose was not
possible in Colorado owing to the small number of subjects. Unvac-
cinated and TIV-vaccinated concurrent controls were matched 1:1
with LAIV recipients, respectively. If a match could not be found
within a speciﬁc control group, the LAIV recipient was excluded
from the cohort comparison. Study day 0 for each participant in the
LAIV-vaccinated group was  the date of receipt of the ﬁrst dose of the
current seasonal LAIV formulation. Study day 0 for each unvacci-
nated and TIV-vaccinated matched concurrent control was deﬁned
as the date of vaccination of the reference LAIV recipient or the date
of the ﬁrst dose of current TIV, respectively. Subsequent study days
were numbered sequentially thereafter.
2.3. Outcome measures
Diagnoses  from all MAEs occurring in study subjects were
collected from outpatient clinic visits, ED visits, and hospital admis-
sions via extraction of records from the KP utilization databases. An
MAE  was  deﬁned as a coded medical diagnosis made by a health-
care provider and associated with a medical encounter. One or more
MAEs could be assigned for a single encounter. MAEs were evalu-
ated regardless of whether the individual had a pre-existing history
of the same or a similar condition; the analysis was  not restricted
to incident MAEs.
Consistent with a prior study of LAIV safety conducted in KP
[3], medical events that were hypothesized a priori as poten-
tially causally related to vaccination based on the pathophysiology
of wild-type inﬂuenza were grouped together in 5 event cate-
gories and analyzed cumulatively across all settings as prespeciﬁed
diagnoses of interest (PSDI), which included (1) acute respira-
tory tract events (ART), (2) acute gastrointestinal tract events
(AGI), (3) asthma and wheezing events (AW), (4) systemic bacterial
R. Baxter et al. / Vaccine 30 (2012) 2989– 2998 2991
Table  1
Summary of safety analyses.
Event Post-vaccination period Clinical setting
Anaphylaxis, urticaria 3 days Clinic, ED,  hospital
Individual  MAEs 21a and 42 days Clinic, ED,  hospital
SAEs 21  and 42 days All
PSDIs  21, 42 and 180b days All
Hospitalizations and deaths for all causes 21, 42 and 180 days Hospital, anyc
Hospitalizations and deaths for rare events potentially related to wild-type inﬂuenza 180 days and entire study periodd Hospital, any
ED, emergency department; MAE, medically attended event; PSDI, prespeciﬁed diagnoses of interest; SAE, serious adverse event.
a The analysis period for the within-cohort group was for 21-day outcomes only.
b Asthma and wheezing events only.
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hc Deaths were assessed in any setting.
d The end of the entire study period was deﬁned as 6 months after completion of
nfections (SBI), and (5) rare diagnoses potentially related to wild-
ype inﬂuenza (WTI). Asthma and wheezing events were a subset
f ART; AW events were followed for 180 days, in contrast to the
2 days surveillance for other PSDIs. These event categories are
etailed in Supplemental Digital Content 1, a table of descriptions
f the prespeciﬁed diagnoses of interest. PSDI events were analyzed
ndividually and cumulatively by category. Individual chart reviews
ere performed for select outcomes of interest to conﬁrm speciﬁc
iagnoses.
SAEs were deﬁned in a similar manner to previous LAIV stud-
es, were identiﬁed from 0 to 42 days postvaccination, and were
eported regardless of the investigator’s assessment of the rela-
ionship to LAIV. Any subsequent serious event that was  considered
o be related to LAIV was also reported as an SAE [4]. Assessment
f the relationship between an SAE and LAIV was conducted by
P staff and based upon the temporal relationship of the event to
he administration of the vaccine, whether an alternative etiology
ould be identiﬁed, and biological plausibility. Pregnancies were
dentiﬁed by obtaining any pregnancy related MAE  within 42 days
f vaccination in any setting or any pregnancy related MAE  in the
D or hospital setting within 180 days of vaccination. Chart review
as performed on any subject with a pregnancy related visit to
erify the pregnancy and obtain outcome information. Information
n deaths in Northern California was obtained from KP databases,
he State of California death certiﬁcate ﬁles, and the Social Security
dministration Death Master File of all known vaccinees from the
tart of the study. These databases were cross-referenced with the
ubject’s medical record.
For  each incidence rate comparison between LAIV recipients and
 control group, a rate ratio was calculated. Rate comparisons of
ndividual MAEs were made for each setting separately; for PSDI,
omparisons were made for all settings combined. For MAEs occur-
ing in the hospital setting, any duration of inpatient hospitalization
as counted, unlike the ≥24-h requirement for an SAE. For each
ontrol group, rate comparisons were made for each period (3, 21,
2, or 180 days or entire study period), age group (5–8, 9–17 years),
etting (clinic, hospital, ED), and dose number for ages 5 to 8 years
s outlined in Table 1.
Asthma  and wheezing events were of particular interest in
his study and were captured in multiple ways. A speciﬁc asthma
nd wheezing analysis was conducted as part of the PSDI analy-
is through 180 days. The term “asthma/reactive airway disease
RAD)” used in this analysis encompassed the individual diagnoses
f asthma, cough variant asthma, and exercise-induced asthma,
nd the term “wheezing/shortness of breath (SOB)” included the
iagnoses of wheezing and dyspnea/SOB. Asthma and wheezing
vents were also captured as part of the PSDI analysis of acute
espiratory tract events in the 21- and 42-day periods. Lastly,
ndividual diagnoses of asthma and wheezing events were ana-
yzed as individual MAEs in each of 3 settings: clinic, ED, and
ospital.rimary dosing regimen by the last person vaccinated within the age cohort.
2.4. Statistical analyses
Event  rates were calculated per 1000 person-months. Relative
risks (RR) were calculated as the ratio of the incidence rates of
the two  comparison groups without adjustment for any covari-
ate. Hazard ratios (HR) were also calculated adjusting for matching
factors and seasonal changes in background rates. Adjusted haz-
ard ratios were obtained from the Cox proportional hazards model
implementing the counting-process style of input [9]. This style of
input facilitated the use of time-dependent covariates and of cal-
endar time as the time structure of the model, which controlled for
any seasonal effects. Analyses modelled the ﬁrst incidence of each
event or class of event (e.g., respiratory events) as the response
variable. The RR for the main effect (or a covariate) was estimated
by eˇ where  ˇ is the regression coefﬁcient for the speciﬁc effect
or covariate of interest. The ninety ﬁve percent conﬁdence inter-
vals for the RR were calculated using a normal approximation, with
the variance derived from the appropriate diagonal element of the
estimated covariance matrix.
In  a conservative approach, statistical signiﬁcance was  declared
if either the exact method or the Cox model showed statistical sig-
niﬁcance. A statistically signiﬁcant increased risk associated with
LAIV vaccination was  declared if the lower bound of the exact 95%CI
or the CI constructed from the Cox proportional model was >1.00.
Likewise, a statistically signiﬁcant decreased risk associated with
LAIV vaccination was declared if the upper bound of either 95%CI
was <1.00. Statistical signiﬁcance was determined before rounding.
The corresponding P values were also provided. When the control
group had a zero event, the RR or HR was not estimable owing to
a zero value of the denominator. If the P value was available, sta-
tistical signiﬁcance was declared according to the P value at the
signiﬁcance level of 0.05.
According  to the prespeciﬁed data analysis plan, CIs were
constructed without multiplicity adjustment. To facilitate inter-
pretation of the results, a post hoc analysis was conducted using
the Bonferroni method and statistical signiﬁcance was declared
at the adjusted signiﬁcance level of 0.000002. The sample size of
20,000 per age group provided ≥90% power within each age group
to observe a statistically signiﬁcant increased RR if the true RR was
≥2.0 for events that occurred at a rate of 1 in 500 or if the true RR
was ≥2.5 for events that occurred at a rate of 1 in 1000. For events
that occurred at rates of 1 in 100 or 1 in 50, the study provided ≥90%
power to observe a statistically signiﬁcant increased RR if the true
RR was ≥1.4 or ≥1.25, respectively, in each age cohort. All analyses
were performed using SAS® statistical software, version 8.2 (SAS
Institute, Inc., Cary, NC, USA).3. Results
A total of 43,702 unique subjects 5–17 years of age were vac-
cinated with 53,369 doses of Ann Arbor strain LAIV during the 5
2992 R. Baxter et al. / Vaccine 30 (2012) 2989– 2998
Table  2
Characteristics of subjects receiving vaccine doses in all analyses.a
Subject characteristics, n (%) Type of analysis
Within-cohort comparison
(self-controlled)
Comparison  with unvaccinated controls Comparison with TIV controls
LAIV doses (N = 53,369) LAIV doses (N = 53,366) Unvaccinated (N = 53,366) LAIV doses (N = 48,683) TIV doses (N = 48,683)
Age category
3–4  yearsa 0 (0.0%) 0 (0.0%) 172 (0.3%) 0 (0.0%) 1683 (3.5%)
5–8  years 23,530 (44.1%) 23,528 (44.1%) 23,362 (43.8%) 21,312 (43.8%) 19,631 (40.3%)
9–17  years 29,839 (55.9%) 29,838 (55.9%) 29,794 (55.8%) 27,371 (56.2%) 27,211 (55.9%)
18–19  yearsa 0 (0.0%) 0 (0.0%) 38 (0.1%) 0 (0.0%) 158 (0.3%)
Sex
Female  28,123 (52.7%) 28,121 (52.7%) 28,121 (52.7%) 25,487 (52.4%) 25,487 (52.4%)
Male 25,246 (47.3%)  25,245 (47.3%) 25,245 (47.3%) 23,196 (47.6%) 23,196 (47.6%)
Healthcare utilization
Low  (0 or 1 visit) 37,940 (71.1%) 37,939 (71.1%) 37,939 (71.1%) 37,731 (71.3%) 34,731 (71.3%)
High  (2+ visits) 15,429 (28.9%) 15,427 (28.9%) 15,427 (28.9%) 13,952 (28.7%) 13,952 (28.7%)
Region
Colorado 3821  (7.2%) 3821 (7.2%) 3821 (7.2%) 3294 (6.8%) 3294 (6.8%)
Hawaii  3738 (7.0%) 3737 (7.0%) 3737 (7.0%) 3605 (7.4%) 3605 (7.4%)
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AIV, live attenuated inﬂuenza vaccine; TIV, trivalent inactivated inﬂuenza vaccine
a There is one 3-year-old and one 19-year-old in the analysis. Both are TIV contro
tudy seasons. A similar number of TIV-vaccinated subjects receiv-
ng 48,683 vaccine doses and 53,366 unvaccinated subjects were
sed as matched controls. Subject characteristics are summarized
n Table 2.
.1.  Deaths and serious adverse events
A total of 3 deaths from all causes within 180 days of LAIV
accination were observed during the entire study period. Deaths
ncluded a 17-year-old who died in an automobile accident, a 13-
ear-old who died from asphyxiation after choking on food, and an
1-year-old who died in a house ﬁre. All were considered by the
nvestigator to be unrelated to LAIV. During the same time period,
 death occurred in each of the unvaccinated and TIV-vaccinated
ontrol groups. The rate of death was not signiﬁcantly higher in
hose vaccinated with LAIV compared with those unvaccinated or
accinated with TIV.
There  were 68 SAEs (3 in the clinic setting, 1 in the ED setting
nd 64 in the hospital setting) in 64 subjects within 42 days of vac-
ination with LAIV. SAEs within 42 days of vaccination occurred at
n incidence rate of 0.56 and 0.47 per 1000 person-months after the
rst and second dose, respectively, in those 5–8 years of age and at
.08 per 1000 person-months in those 9–17 years of age. Of those
ccurring in 5- to 8-year-olds (n = 19) the most common primary
iagnoses were trauma (n = 4), appendicitis (n = 2) and gastroen-
eritis (n = 2). Of those occurring in 9- to 17-year-olds (n = 49) the
ost common primary diagnoses were psychiatric (n = 17), appen-
icitis (n = 6), and trauma (n = 5). In the analysis, the incidence rates
f SAEs overall and by speciﬁc diagnosis were not signiﬁcantly
igher or lower in LAIV recipients relative to control groups in any
omparison.
Of the SAEs occurring within 42 days postvaccination, only 2
vents were categorized by investigators as possibly related to
AIV. A 9-year-old male subject experienced dystonic tongue pos-
uring 3 days postvaccination that was classiﬁed as a nonspeciﬁc
aroxysmal spell. The subject’s past medical history was signiﬁ-
ant for a previous episode of prolonged dystonic tongue posturing
ollowing a febrile seizure. The subject recovered in full. A case of
ell’s palsy occurred in a 10-year-old male subject 2 days post-
accination. The subject’s past medical history was signiﬁcant for
 visit to the ED for left-sided headache, left-sided facial numb-
ess, and nasal congestion 2 days before receiving LAIV. The subject45,808 (85.8%) 41,784 (85.8%) 41,784 (85.8%)
recovered  in full. In all children 9–17 years of age, Bell’s palsy
occurred in 2, 7, and 0 children vaccinated with LAIV or TIV or
unvaccinated, respectively.
3.2.  Hospitalizations
There were 477 hospitalizations that were observed within 180
days of LAIV vaccination. Among those 5–8 years of age (n = 169)
the most common ﬁrst diagnoses were trauma (n = 31), otitis media
(n = 17), and tonsillitis (n = 15). Most hospitalizations for otitis
media (94%) were for prescheduled tympanostomy tube place-
ments. Among those 9–17 years of age (n = 308), the most common
ﬁrst diagnoses were psychiatric (n = 68), trauma (n = 59) and appen-
dicitis (n = 28). The only diagnoses signiﬁcantly increased in LAIV
recipients relative to control groups were tonsillitis within 42 days
in those 9–17 years of age (LAIV, n = 7; unvaccinated, n = 1) and
trauma within 42 days in those 5–8 (LAIV, n = 8; unvaccinated, n = 1)
and 9–17 (LAIV, n = 13; TIV, n = 4) years of age. All hospitalizations
for tonsillitis were for prescheduled tonsillectomies. One diagnosis
in the hospital setting was signiﬁcantly decreased in LAIV recipi-
ents relative to control groups: pregnancy/delivery within 42 days
in 9- to 17-year-olds (LAIV, n = 0; TIV, n = 9).
There  were 12 hospitalizations in 10 subjects due to rare diag-
noses potentially related to wild-type inﬂuenza from vaccination to
the end of the study period (end of surveillance for the ﬁnal study
subject); 1 subject was hospitalized 3 times for viral encephali-
tis. The only rare diagnosis event present in more than 1 subject
was viral meningitis (n = 5). One death due to viral myocarditis
occurred 1586 days postvaccination. No event was  considered by
investigators to be causally related to LAIV. In the analysis, no rare
diagnosis potentially related to wild-type inﬂuenza was signiﬁ-
cantly increased or decreased in LAIV recipients relative to control
groups in any comparison.
3.3.  All medically attended events
To analyze the many rate comparisons for individual MAEs that
occurred at a signiﬁcantly higher or lower rate among LAIV recip-
ients within the varied aged groups, settings, time intervals and
dose number, graphic representations were constructed. The sta-
tistically signiﬁcant differences are represented in 2-dimensional
“heat map” graphics, similar to those commonly used to display
R. Baxter et al. / Vaccine 30 (2012) 2989– 2998 2993
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Developmental Delay
Well Care/Reassurance/FU
Drug Reaction
Cyst
Speech Therapy
Elective Procedure
Congenital Anomaly
Cerebral Palsy
Chalazion
Vision Disorder
Heart Murmur
Positive PPD Test
ADD/ADHD
Asperger’s Syndrome
Psychiatric
Encopresis
Addiction
Poisoning/Ingestion
Foreign Body
Trauma
Postsurgical State/Complication
Benign Lesion
Urticaria
Contact Dermatitis
Eczema
Pityriasis Rosea
Pruritus
Rash
Arthritis/Arthralgia
Musculoskeletal Pain
Asthma
Wheezing
Cough
Allergic Rhinitis/Rhinitis
Epistaxis
Pharyngitis
Sinusitis
URI
Otitis Media
Otitis Media with Effusion
Scarlet Fever
Vaginitis/Vulvovaginitis
Pneumonia
UTI
Influenza
Molluscum
Dental
Gingivitis
Diarrhea
Pain, Abdominal
Allergy, Drug
Obesity
Dehydration
Balanitis
Urethra /Urinary Tract Disorder NOS
Dysuria
Nephrolithiasis
Otalgia
Cerumen Impaction
Eustachian Tube Dysfunction
Seizure, Afebrile
Adenitis
21D=21 days postvaccination; 42D=42 days postvaccination; ADD/ADHD=attention deficit disorder/attention deficit hyperactivity disorder; 
D1=dose 1; D2=dose 2; ED=emergency department; Hosp=hospitalization; FU=follow-up; LAIV=live attenuated influenza vaccine; 
MAE=medically attended adverse event; MedDRA=Medical Dictionary for Regulatory Activities; NOS=not otherwise specified; 
SOC=system organ class; TIV=trivalent inactivated influenza vaccine; URI=upper respiratory tract infection; UTI=urinary tract infection.
Any EventGeneral disorders
and administration
site conditions
Surgical and medical
procedures
Congenital, familial
and genetic disorders
Eye disorders
Investigations
Psychiatric disorders
Injury, poisoning
and procedural
complications
Neoplasms benign, malignant, and unspecified
Skin and subcutaneous
tissue disorders
Musculoskeletal and
connective tissue disorders
Respiratory, thoracic
and mediastinal
disorders
Infections and infestations
Renal and
urinary disorders
MedDRA SOC MAE Term
Gastrointestinal disorders
Immune system disorders
Metabolism and
nutrition disorders
Reproductive/breast disorders
Ear and labyrinth
disorders
Nervous system disorders
Blood/lymphatic system disorders
Fig. 1. Statistically signiﬁcant differences in individual MAEs in LAIV recipients 5–8 years of age relative to controls. Individual medically attended events (MAEs) are grouped
by  organ class and medical term according to the Medical Dictionary for Regulatory Activities (MEDRA) along ﬁgure rows. Columns represent individual analyses which are
organized  by comparison group (versus trivalent inactivated inﬂuenza vaccine [TIV], unvaccinated, within cohort), location (clinic, emergency department [ED], hospital
[Hosp]), dose number (dose 1 [D1] and dose 2 [D2]) and time interval (21 days [21D] and 42 days [42D]). Events occurring at a signiﬁcantly higher rate after live attenuated
inﬂuenza vaccine (LAIV) are coded orange and those occurring at a signiﬁcantly lower rate after LAIV are coded in blue. The within-cohort analysis (self-control) columns
are fewer in number because this analysis was performed within the 21-day postvaccination interval only. The majority of signiﬁcant events occurred in the clinic setting
after  dose 1. Most events occurring at a higher rate after LAIV (orange) are found within the unvaccinated comparison group columns whereas most events that occurred
at a lower rate after LAIV (blue) are found within the TIV-vaccinated comparison group columns. Events counted as part of the prespeciﬁed diagnoses of interest and those
occurring within 3 and 180 days of vaccination are not included in the ﬁgure. Events listed are those which were signiﬁcant prior to the adjustment for multiple comparisons.
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vs TIV vs Unvaccinated within Cohort
Fatigue
Local Swelling
Well Care/Reassurance/FU
Cyst
Speech Therapy
Elective Procedure
Pregnancy - Delivery
Pregnancy - Exam/Supervision
Congenital Heart Disease
Congenital Anomaly
Cerebral Palsy
Dry Eye Syndrome
Glaucoma
Chalazion
Vision Disorder
Heart Murmur
Positive PPD Test
Short Stature
Weight Loss
Stress Reaction
ADD/ADHD
Depression
Asperger’s Syndrome
Behavioral Disorder
Psychiatric
Addiction
Sleep Disorder
Learning Disability
Foreign Body
Trauma
Postsurgical State/Complication
Warts
Benign Lesion
Neoplasm NOS
Rash
Scar
Pigmentation, Hyper or Hypo
Acne
Alopecia
Nail Disorder
Seborrhea
Scoliosis
Pain, Back
Musculoskeletal Pain
Asthma
Asthma, Exercise Induced
Wheezing
Cough
Snoring
Allergic Rhinitis/Rhinitis
Sinusitis
Tonsilitis
URI
Otitis Externa
Otitis Media
Abcess/Cellulitis
Parasite Infestation
Tinea
Gastroenteritis
Vaginitis/Vulvovaginitis
Impetigo
UTI
Herpes Zoster
Influenza
Dental
Colitis, Ulcerative
Colitis, Crohn’s
GE Reflux 
Allergic Reaction
Allergy, Food
Obesity
Diabetes
Breast Lump/Cyst
Polycystic Ovarian Syndrome
Varicocele
Genital Pain
Enuresis
Cerumen Impaction
Vertigo
Eustachian Tube Dysfunction
Tympanic Membrane Perforation
Headache
Migraine
Ataxia
Dizziness
Speech Delay
Seizure, Afebrile
Epilepsy
Anemia
Any EventGeneral disorders
and administration
site conditions
Surgical and medical
procedures
Pregnancy, puerperium and
perinatal conditions
Congenital, familial
and genetic disorders
Eye disorders
Investigations
Psychiatric disorders
Neoplasms benign, malignant,
and unspecified
Skin and subcutaneous
tissue disorders
Musculoskeletal and
connective tissue disorders
Respiratory, thoracic
and mediastinal
disorders
Infections and infestations
Social circumstances
Injury, poisoning
and procedural
complications
Renal and urinary disorders
MedDRA SOC MAE Term
Gastrointestinal disorders
Immune system disorders
Metabolism and
nutrition disorders
Reproductive/breast disorders
Ear and labyrinth
disorders
Nervous system disorders
Blood/lymphatic system disorders
21D=21 days postvaccination; 42D=42 days postvaccination; ADD/ADHD=attention deficit disorder/attention deficit hyperactivity disorder; 
D1=dose 1; D2=dose 2; ED=emergency department; Hosp=hospitalization; FU=follow-up; LAIV=live attenuated influenza vaccine; 
MAE=medically attended adverse event; MedDRA=Medical Dictionary for Regulatory Activities; NOS=not otherwise specified; 
SOC=system organ class; TIV=trivalent inactivated influenza vaccine; URI=upper respiratory tract infection; UTI=urinary tract infection.
Fig. 2. Statistically signiﬁcant differences in individual MAEs in LAIV recipients 9–17 years of age relative to controls. Individual medically attended events (MAEs) are
grouped by organ class and medical term according to the Medical Dictionary for Regulatory Activities (MEDRA) along ﬁgure rows. Columns represent individual analyses
which are organized by comparison group (versus trivalent inactivated inﬂuenza vaccine [TIV], unvaccinated, within cohort), location (clinic, emergency department [ED],
hospital  [Hosp]), dose number (dose 1 [D1] and dose 2 [D2]) and time interval (21 days [21D] and 42 days [42D]). Events occurring at a signiﬁcantly higher rate after live
attenuated inﬂuenza vaccine (LAIV) are coded orange and those occurring at a signiﬁcantly lower rate after LAIV are coded in blue. The within-cohort analysis (self-control)
ine 30
u
(
(
w
i
a
c
f
l
d
t
f
t
1
w
r
s
s
t
w
c
r
p
a
a
R
L
a
d
d
i
r
U
7
w
d
l
s
p
w
a
r
i
t
c
i
e
l
i
E
r
s
i
A
t
t
i
c
s
o
a
cR. Baxter et al. / Vacc
p- and downregulation of various associated gene segments [10]
Figs. 1 and 2).
Of  the 9496 incidence rate comparisons performed, a total of 372
4%) yielded statistically signiﬁcant differences: 204 incidence rates
ere higher and 168 incidence rates were lower in LAIV recipients
n comparison with any of the 3 control groups in various settings
nd within various time frames postvaccination. Of the 372 rate
omparisons, 307 were from individual MAE  terms and 65 were
rom PSDIs. Of the 65 signiﬁcant comparisons from the PSDI col-
ected across all settings 45 came from individual diagnoses; these
ifferences were also identiﬁed as elevated MAEs in the clinic set-
ing (Figs. 1 and 2). The remaining 20 PSDI comparisons resulted
rom analyses of any acute respiratory tract, acute gastrointestinal
ract, or asthma and wheezing events (Table 3). By control group,
55 (76%) of the rate comparisons that were increased after LAIV
ere in relationship to unvaccinated controls, and 126 (75%) of the
ate comparisons that were decreased after LAIV were in relation-
hip to TIV-vaccinated controls.
The majority of signiﬁcant individual MAEs occurred in the clinic
etting (96%), only 3% and 1% occurred in the ED and hospital set-
ings, respectively. Only 1 MAE  rate comparison was associated
ith a signiﬁcant increase among LAIV recipients relative to all 3
ontrol groups. There were 7 events of breast lump/cyst in LAIV
ecipients 9–17 years of age in the clinic setting through 21 days
ostvaccination and no events in the TIV-vaccinated, unvaccinated
nd within-cohort controls. Five of these events were preexisting,
nd 1 event appeared to be gynecomastia in an adolescent male.
espiratory events were found to occur at a lower rate among
AIV recipients in comparison with TIV-vaccinated controls. In both
ge groups, medically attended events related to psychiatric disor-
ers overall and speciﬁcally for attention deﬁcit disorder/attention
eﬁcit hyperactivity disorder (ADD/ADHD), depression and behav-
oral disorders were found to occur at an increased rate in LAIV
ecipients compared with TIV recipients and those unvaccinated.
pon review of subjects with psychiatric disorders, approximately
0% had evidence of prior healthcare visits for similar diagnoses
ithin the Kaiser Permanente database; overall and for speciﬁc
iagnoses, the proportion with evidence of prior visits was  simi-
ar for LAIV and controls. A temporal analysis of these conditions
howed no evidence of clustering of events within the 42 days
ostvaccination.
Asthma and wheezing events were evaluated in detail. There
ere a total of 17 statistically signiﬁcant rate comparisons in the
sthma and wheezing PSDI analysis; all events occurred at lower
ates in LAIV recipients relative to controls. For asthma and wheez-
ng events captured under the PSDI category of acute respiratory
ract events, 7 rate comparisons of asthma/RAD events and 3 rate
omparisons of wheezing/SOB events were signiﬁcantly decreased
n LAIV recipients relative to controls. For asthma and wheezing
vents analyzed by individual MAEs, asthma events occurred at a
ower rate in LAIV recipients relative to controls in 7 rate compar-
sons in the clinic setting and 1 rate comparison in the ED setting.
xercise-induced asthma events occurred at lower rates in LAIV
ecipients relative to controls in 2 rate comparisons in the clinic
etting, and wheezing events occurred at lower rates in LAIV recip-
ents relative to controls in 3 rate comparisons in the clinic setting.
ll but 1 of these rate comparisons occurred in comparison with
hose vaccinated with TIV. There were no asthma/wheezing events
hat occurred at a higher rate in LAIV recipients relative to controls
n any of the above analyses (see Supplemental Digital Content 2,
olumns are fewer in number because this analysis was performed within the 21-day pos
etting after dose 1. Most events occurring at a higher rate after LAIV (orange) are foun
ccurred at a lower rate after LAIV (blue) are found within the TIV-vaccinated compariso
nd those occurring within 3 and 180 days of vaccination are not included in the ﬁgure. E
omparisons. (2012) 2989– 2998 2995
which shows hazard ratios of asthma and wheezing events after
vaccination with LAIV versus comparators).
No anaphylaxis events occurred within the 3-day risk period
postvaccination in either LAIV recipients or any control group.
Within 3 days of LAIV vaccination there were 9 cases of urticaria
(8 in the clinic setting and 1 in the ED setting). The rate of urticaria
within 3 days of vaccination was  not signiﬁcantly increased or
decreased in LAIV recipients relative to control groups in any com-
parison.
After the post hoc adjustment for multiple comparisons, 48 of
the 372 incidence rate comparisons remained statistically signiﬁ-
cant (Tables 4 and 5). In children 5–8 years of age, events occurring
at an increased rate after vaccination with LAIV were psychiatric
conditions, vision disorders, and well care visits; all were rela-
tive to unvaccinated controls. Events occurring at a lower rate
after vaccination with LAIV included any acute respiratory tract
event, any asthma and wheezing event, asthma and asthma/RAD;
all were relative to TIV-vaccinated controls. For children 9–17 years
of age, events occurring at a higher rate after vaccination with LAIV
included those associated with routine well/preventive care, psy-
chiatric conditions, and trauma; all were relative to unvaccinated
controls. Any event in the clinic setting was also increased rela-
tive to unvaccinated controls. Events occurring at a lower rate after
vaccination with LAIV included any acute respiratory tract event,
any asthma and wheezing event, addiction, asthma, dental condi-
tions, postsurgical state/complication and pregnancy examination;
all were relative to TIV-vaccinated controls. Pregnancy examination
was also decreased relative to unvaccinated controls.
A  total of 10 pregnancies were noted in LAIV recipients 14–17
years of age. Two subjects were vaccinated before their last men-
strual period, 7 were vaccinated in the ﬁrst trimester, and 1 was
vaccinated in the second trimester. Of the 9 pregnancies with
known outcomes, 6 had elective abortions, 1 had a spontaneous
abortion, and 2 had live births. The 2 live births were both full-term
infants with no noted adverse events or congenital anomalies.
4.  Discussion
This study evaluated the rate of MAEs, SAEs, hospitalizations,
and deaths after LAIV vaccination in patients 5–17 years of age
compared with the rates in 3 different sets of controls, in a total
of 131,854 children, representing the largest safety study of LAIV
to date. SAEs within 42 days of vaccination were uncommon,
and the most common diagnoses found (psychiatric conditions,
appendicitis, and trauma) mirrored the most common causes for
hospitalization in children younger than 15 years [11]. Only 2 SAEs
were considered to be possibly related to the vaccine, and the sub-
jects both had a history of the event or preexisting symptoms of
the condition. Anaphylaxis after LAIV vaccination was not seen, and
urticaria within 3 days of vaccination was  uncommon. Similar to an
analysis from the Vaccine Adverse Events Reporting System from
the ﬁrst 2 postlicensure years of LAIV, this study did not identify
any unexpected serious risks when the vaccine was used in the
approved population [12].
Because of the exploratory nature of this study and the lack oftvaccination interval only. The majority of signiﬁcant events occurred in the clinic
d within the unvaccinated comparison group columns whereas most events that
n group columns. Events counted as part of the prespeciﬁed diagnoses of interest
vents listed are those which were signiﬁcant prior to the adjustment for multiple
formal hypothesis testing, no corrections were made for multiple
comparisons in the prespeciﬁed analysis. As a result, owing to the
large number of rate comparisons, one would expect many statis-
tically signiﬁcant results. Most of the events occurring at a higher
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Table  3
Statistically signiﬁcant differences in prespeciﬁed diagnoses of interest by group.
Diagnosis Control Risk period (days) Age group (years) LAIV ratea Control ratea HR HR 95%CI
Any acute gastrointestinal tract event Unvaccinated 21 5–8 8.58 6.32 1.36 (1.05, 1.76)
Any  acute gastrointestinal tract event Unvaccinated 42 5–8 8.48 6.50 1.30 (1.08, 1.57)
Any  acute respiratory tract event TIV  21 5–8 43.93 57.32 0.77 (0.69, 0.86)
Any  acute respiratory tract event Unvaccinated 21 5–8 45.03 40.29 1.12 (1.00, 1.25)
Any  acute respiratory tract event Within 21 5–8 45.03 53.70 0.96 (0.85, 1.07)
Any  acute respiratory tract event TIV 42 5–8 46.94 56.57 0.82 (0.77, 0.89)
Any  acute respiratory tract event Unvaccinated 42 5–8 47.54 41.51 1.15 (1.06, 1.24)
Any  acute respiratory tract event Unvaccinated 42 5–8 72.65 52.22 1.39 (1.08, 1.78)
Any  acute respiratory tract event TIV 21 9–17 25.83 32.71 0.80 (0.71, 0.90)
Any  acute respiratory tract event TIV  42 9–17 25.75 34.07 0.77 (0.70, 0.83)
Any  asthma or wheezing event TIV 21 5–8 3.07 10.07 0.29 (0.21, 0.41)
Any  asthma or wheezing event Within 21 5–8 3.28 5.59 0.84 (0.57, 1.24)
Any  asthma or wheezing event TIV 42 5–8 4.11 10.28 0.38 (0.30, 0.47)
Any  asthma or wheezing event TIV 42 5–8 7.10 14.99 0.46 (0.21, 0.97)
Any  asthma or wheezing event TIV 180 5–8 5.88 11.45 0.51 (0.46, 0.56)
Any  asthma or wheezing event TIV  180 5–8 5.76 11.40 0.51 (0.33, 0.77)
Any  asthma or wheezing event TIV 21 9–17 2.43 7.15 0.33 (0.24, 0.46)
Any  asthma or wheezing event TIV 42 9–17 2.70 7.57 0.35 (0.28, 0.44)
Any  asthma or wheezing event TIV 180 9–17 3.96 9.41 0.42 (0.38, 0.46)
Any  asthma or wheezing event Unvaccinated 180 9–17 4.00 4.81 0.83 (0.75, 0.92)
HR, hazard ratio; LAIV, live attenuated inﬂuenza vaccine; NE, not estimated; TIV, trivalent inactivated inﬂuenza vaccine.
There were no statistically signiﬁcant comparisons for the groups systemic bacterial infections and rare diagnoses potentially related to wild-type inﬂuenza infection.
a Rate per 1000 person months
Table 4
Statistically signiﬁcant differences in events after multiplicity adjustment in LAIV recipients 5–8 years of age.
Control Period (days) Setting LAIV ratea Control ratea HR HR 95%CI Event category
Increased events
Psychiatric Unvaccinated 42 Clinic 13.94 8.91 1.57 (1.35, 1.83) MAE
Vision  disorder Unvaccinated 21 Clinic 15.07 7.61 1.98 (1.59, 2.47) MAE
Vision  disorder Unvaccinated 42 Clinic 12.50 7.85 1.59 (1.35, 1.87) MAE
Well  care/reassurance/FU Unvaccinated 21 Clinic 55.36 36.12 1.53 (1.38, 1.71) MAE
Well  care/reassurance/FU Unvaccinated 42 Clinic 50.68 34.09 1.49 (1.37, 1.61) MAE
Decreased  events
Any  acute respiratory tract event TIV 21 All 43.93 57.32 0.77 (0.69, 0.86) PSDI
Any  acute respiratory tract event TIV 42 All 46.94 56.57 0.83 (0.77, 0.89) PSDI
Any  asthma or wheezing event TIV  180 All 5.88 11.45 0.51 (0.46, 0.56) PSDI
Any  asthma or wheezing event TIV 21 All 3.07 10.07 0.29 (0.21, 0.41) PSDI
Any  asthma or wheezing event TIV 42 All 4.11 10.28 0.38 (0.30, 0.47) PSDI
Asthma TIV 21 Clinic 1.19 6.92 0.16 (0.09, 0.26) MAE
Asthma  TIV 42 Clinic 2.23 7.20 0.29 (0.22, 0.38) MAE
Asthma/RAD TIV 180 All 3.87 9.14 0.42 (0.37, 0.47) PSDI
Asthma/RAD TIV 21 All 1.19 7.13 0.15 (0.09, 0.26) PSDI
Asthma/RAD TIV 42 All 2.23 7.45 0.28 (0.21, 0.37) PSDI
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pU, follow-up; HR, hazard ratio; LAIV, live attenuated inﬂuenza vaccine; MAE, m
isease; TIV, trivalent inactivated inﬂuenza vaccine.
a Rate per 1000 person months.
ate after vaccination with LAIV were found in comparison with
nvaccinated controls whereas most of the events occurring at a
ower rate after vaccination with LAIV were found in comparison
ith TIV-vaccinated controls. These differences are most likely the
esult of underlying differences in the nonrandomized comparison
roups that remained despite subject matching.
Given the warning against use of LAIV in individuals with under-
ying medical conditions, it is likely that TIV-vaccinated controls
ad a poorer health status relative to LAIV-vaccinated controls,
ven after exclusion of individuals with identiﬁable high-risk
nderlying medical conditions from the analysis populations. This
nderlying bias is consistent with the ﬁndings of decreased rates of
espiratory events among LAIV recipients relative to TIV-vaccinated
ontrols that remained after adjusting for multiple comparisons.
It  also appears likely that despite matching there were underly-
ng differences between LAIV recipients and unvaccinated controls,
ith unvaccinated controls being less likely to access vaccination
nd healthcare in general. This could explain the increased rate of
vents related to routine preventive care in LAIV recipients com-
ared with those unvaccinated, such as well visits, vision disorder (aly attended event; PSDI, prespeciﬁed diagnoses of interest; RAD, reactive airway
combination of codes including myopia, hyperopia, and other rou-
tine visual disorders), acne, obesity, nail disorder, and congenital
anomaly (given the age of our study population this code repre-
sented pre-existing congenital anomalies, not those in the offspring
of a study subject).
A  selection bias for or against LAIV in individuals with cer-
tain medical conditions could result in an apparent increased
or decreased rate of the condition in LAIV recipients compared
with controls. This phenomenon explains the decreased rates of
pregnancy-related events among LAIV recipients; there is a warn-
ing against the use of LAIV in pregnant women. Similarly, the
increased rates of some psychiatric and behavioral disorders such
as attention deﬁcit disorder/attention deﬁcit hyperactivity disor-
der and depression among LAIV recipients 9–17 years of age appear
to be the result of individuals with those conditions selecting LAIV
because of its intranasal administration or its lack of thimerosal and
other preservatives. This selection bias has been observed in analy-
ses of children receiving LAIV versus TIV in a large, national private
insurance claims database, MarketScan® Research Data (Thomson
Reuters, New York, NY, USA). Other notable ﬁndings were those
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Table  5
Statistically signiﬁcant differences in events after multiplicity adjustment in LAIV recipients 9–17 years of age.
Control Period (days) Setting LAIV ratea Control ratea HR 95%CI Event category
Increased events
Acne Unvaccinated 42 Clinic 7.89 4.72 1.67 (1.40, 2.00) MAE
ADD/ADHD Unvaccinated 42 Clinic 11.42 6.85 1.67 (1.44, 1.94) MAE
Any  event Unvaccinated 21 Clinic 203.93 139.60 1.46 (1.39, 1.54) MAE
Any  event Unvaccinated 42 Clinic 182.69 126.07 1.45 (1.40, 1.51) MAE
Benign  lesion Unvaccinated 42 Clinic 3.10 1.44 2.15 (1.58, 2.92) MAE
Congenital  anomaly Unvaccinated 21 Clinic 3.85 1.33 2.90 (1.88, 4.45) MAE
Congenital  anomaly Unvaccinated 42 Clinic 3.13 1.47 2.13 (1.57, 2.89) MAE
Nail  disorder Unvaccinated 21 Clinic 2.90 0.66 4.36 (2.44, 7.79) MAE
Nail  disorder Unvaccinated 42 Clinic 2.38 0.91 2.61 (1.80, 3.79) MAE
Obesity Unvaccinated 42 Clinic 4.72 2.12 2.23 (1.73, 2.87) MAE
Psychiatric  Unvaccinated 21 Clinic 33.17 23.30 1.43 (1.27, 1.60) MAE
Psychiatric  Unvaccinated 42 Clinic 26.41 17.78 1.49 (1.36, 1.64) MAE
Trauma  Unvaccinated 42 Clinic 22.92 16.94 1.35 (1.23, 1.49) MAE
Vision  disorder Unvaccinated 21 Clinic 21.41 9.14 2.34 (1.98, 2.77) MAE
Vision  disorder Unvaccinated 42 Clinic 18.37 8.21 2.24 (1.97, 2.54) MAE
Well  care/reassurance/FU Unvaccinated 21 Clinic 72.98 48.49 1.51 (1.39, 1.63) MAE
Well  care/reassurance/FU Unvaccinated 42 Clinic 68.43 46.14 1.48 (1.40, 1.57) MAE
Decreased  events
Addiction  TIV 21 Clinic 2.07 6.37 0.32 (0.23, 0.46) MAE
Addiction  TIV 42 Clinic 2.15 5.94 0.37 (0.28, 0.47) MAE
Any  acute respiratory tract event TIV 42 All 25.75 34.07 0.77 (0.70, 0.83) PSDI
Any  asthma or wheezing event TIV 180 All 3.97 9.41 0.42 (0.38, 0.46) PSDI
Any  asthma or wheezing event TIV 21 All 2.43 7.15 0.33 (0.24, 0.46) PSDI
Any  asthma or wheezing event TIV 42 All 2.70 7.57 0.35 (0.28, 0.44) PSDI
Asthma TIV 21 Clinic 1.50 5.08 0.29 (0.19, 0.44) MAE
Asthma  TIV 42 Clinic 1.60 5.54 0.28 (0.21, 0.37) MAE
Asthma/RAD TIV 180 All 3.08 8.25 0.37 (0.33, 0.41) PSDI
Asthma/RAD TIV 21 All 1.71 5.70 0.28 (0.19, 0.42) PSDI
Asthma/RAD TIV 42 All 1.81 6.33 0.28 (0.21, 0.36) PSDI
Dental TIV 42 Clinic 0.65 2.36 0.28 (0.18, 0.43) MAE
Postsurgical  state/complication TIV 42 Clinic 0.03 0.60 0.04 (0.01, 0.32) MAE
Pregnancy  – exam/supervision TIV 21 Clinic 0.05 2.07 0.02 (0.00, 0.18) MAE
Pregnancy  – exam/supervision Unvaccinated 42 Clinic 0.02 0.58 0.04 (0.01, 0.31) MAE
Pregnancy  – exam/supervision TIV 42 Clinic 0.03 1.49 0.02 (0.00, 0.13) MAE
ADD/ADHD, attention deﬁcit disorder/attention deﬁcit hyperactivity disorder; FU, follow up; HR, hazard ratio; LAIV, live attenuated inﬂuenza vaccine; MAE, medically
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a Rate per 1000 patient months.
elated to inﬂuenza. The lower rates of inﬂuenza in children 5–8
ears of age within 42 days of vaccination compared with those
nvaccinated or vaccinated with TIV are likely a result of the efﬁ-
acy of LAIV and high rate of medically attended inﬂuenza illness
n this age group. Among those 9–17 years of age, there was  an
ncrease in inﬂuenza within 21 days of vaccination in the within-
ohort analysis. This could be due to lower vaccine efﬁcacy in
he period immediately following vaccination, while protective
mmune responses are still developing, or due to exposure to wild-
ype inﬂuenza at the time of vaccination. Additionally, it could
e due to individuals with other respiratory illnesses being diag-
osed with inﬂuenza owing to detection of LAIV vaccine strains by
oint-of-care testing. Although no reduction in inﬂuenza related
ospitalizations was seen among those vaccinated with LAIV com-
ared with unvaccinated subjects, the study was  not designed
r powered to detect such a difference, most notably because
ospitalizations suspected to be caused by inﬂuenza were not sys-
ematically tested or identiﬁed.
Despite  the underlying differences in LAIV-vaccinated, TIV-
accinated, and unvaccinated populations, the inclusion of
IV-vaccinated and unvaccinated control groups in the study
esign was valuable to enhance the ability to interpret the study
ata. If there had been a large, true increased risk of a speciﬁc
vent among LAIV recipients, it would have been detectable in
omparison with TIV-vaccinated controls despite the underlying
ifferences in the study populations. Similarly, the lack of an
ncrease relative to unvaccinated controls despite the underlying
ias provides evidence that an event is likely not increased in LAIVV, trivalent inactivated inﬂuenza vaccine.
recipients.  However, given the underlying biases for the compar-
isons to TIV-vaccinated and unvaccinated controls, the single most
valuable comparison appears to be the self-control analysis as it
controls for many of the covariates that are uncontrolled in anal-
yses comparing disparate groups. It is reassuring that very few
events were detected at an increased rate after LAIV vaccination
in the self-control analysis, that those detected were generally due
to minor illness, and that no statistically signiﬁcant differences
in the self-control analyses remained after adjusting for multiple
comparisons.
Because previous studies demonstrated that LAIV was  associ-
ated with an increase in medically attended wheezing events in
young children [3,4], a comprehensive analysis of wheezing and
asthma events was conducted. Events of asthma and wheezing
were found to be decreased after vaccination with LAIV in all set-
tings combined, the clinic setting, and the ED setting; within 21,
42, and 180 days of vaccination; in both age groups; after dose 1
and dose 2; and in comparison to all 3 control groups. There were
no increased rates of events of asthma and wheezing after LAIV
in any rate comparisons. As described above, differences in the
health status of the 2 populations likely explain the reduced rates
of events within the LAIV-vaccinated versus TIV-vaccinated pop-
ulations. However, it is reassuring that the rate of wheezing and
asthma was not increased in any comparisons, particularly those
compared with unvaccinated subjects and the self-control analysis.
Strengths of the current study include the large sample size, the
ability to examine all MAEs for any diagnosis, and the ability to cap-
ture events after the real-world use of LAIV over multiple inﬂuenza
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easons. However, as discussed above, the nonrandomized design
f the study is likely responsible for many of the observed differ-
nces between comparison groups. Furthermore, this study design
id not allow for the systematic determination of whether an event
bserved after vaccination was the result of a pre-existing condi-
ion; evaluations of prior medical history were only feasible for
elect subjects through detailed chart review. Finally, it is impor-
ant to note that inferences drawn from the evaluated KP members
ay not be completely generalizable to the overall US population.
.  Conclusion
In summary, in this study of more than 40,000 LAIV recipients
–17 years of age, rates of MAEs and SAEs were compared between
AIV-vaccinated individuals and multiple nonrandomized controls.
AEs and hospitalizations after vaccination with LAIV were uncom-
on, and no pattern of MAEs was found to occur at higher rates
han control groups. The results of this study are consistent with
reapproval studies [3,13,14] and with reports to the Vaccine
dverse Events Reporting System in the years after the initial
pproval of LAIV [12], which demonstrated no signiﬁcant adverse
utcomes after receipt of LAIV by eligible individuals 5–17 years of
ge. A similar study is currently underway in children 2–4 years of
ge.
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